A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Completed · Phase 3

Conditions studied: Open-Angle Glaucoma, Ocular Hypertension

In brief

This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

Key facts

Study ID

NCT04285580

Run by

AbbVie

People needed

37

Starts

2020-06-11

Expected to finish

2022-05-14

Last updated by the study team

2023-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment
• Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months

You may not qualify if…

• Current or anticipated enrollment in another investigational drug or device study
• Females who are pregnant, nursing, or planning a pregnancy during the study

Where it is running

• Trinity Research Group /ID# 232749 — Dothan, Alabama, United States
• The Eye Research Foundation /ID# 232694 — Newport Beach, California, United States
• Coastal Research Associates /ID# 232798 — Roswell, Georgia, United States
• James D Branch MD /ID# 232718 — Winston-Salem, North Carolina, United States
• Scott and Christie and Associates /ID# 232747 — Cranberry Township, Pennsylvania, United States
• Keystone Research LTD /ID# 232665 — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.